tetano
Editor, Senior Moderator
Proc Natl Acad Sci U S A. 2017 Sep 5. pii: 201707950. doi: 10.1073/pnas.1707950114. [Epub ahead of print]
[h=1]Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.[/h] Maamary J[SUP]1[/SUP], Wang TT[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Tan GS[SUP]4[/SUP], Palese P[SUP]4[/SUP], Ravetch JV[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The main barrier to reduction of morbidity caused by influenza is the absence of a vaccine that elicits broad protection against different virus strains. Studies in preclinical models of influenza virus infections have shown that antibodies alone are sufficient to provide broad protection against divergent virus strains in vivo. Here, we address the challenge of identifying an immunogen that can elicit potent, broadly protective, antiinfluenza antibodies by demonstrating that immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihemagglutinin antibodies. Further, we found that an Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin can be combined with TIV to elicit broad protection, thus setting the stage for a universal influenza virus vaccine.
[h=4]KEYWORDS:[/h] CD23; TIV; immune complex; sialylated Fc; universal influenza vaccine
PMID: 28874545 DOI: 10.1073/pnas.1707950114
[h=1]Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.[/h] Maamary J[SUP]1[/SUP], Wang TT[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3[/SUP], Tan GS[SUP]4[/SUP], Palese P[SUP]4[/SUP], Ravetch JV[SUP]5[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] The main barrier to reduction of morbidity caused by influenza is the absence of a vaccine that elicits broad protection against different virus strains. Studies in preclinical models of influenza virus infections have shown that antibodies alone are sufficient to provide broad protection against divergent virus strains in vivo. Here, we address the challenge of identifying an immunogen that can elicit potent, broadly protective, antiinfluenza antibodies by demonstrating that immune complexes composed of sialylated antihemagglutinin antibodies and seasonal inactivated flu vaccine (TIV) can elicit broadly protective antihemagglutinin antibodies. Further, we found that an Fc-modified, bispecific monoclonal antibody against conserved epitopes of the hemagglutinin can be combined with TIV to elicit broad protection, thus setting the stage for a universal influenza virus vaccine.
[h=4]KEYWORDS:[/h] CD23; TIV; immune complex; sialylated Fc; universal influenza vaccine
PMID: 28874545 DOI: 10.1073/pnas.1707950114